Altamira Therapeutics Stock Price, News & Analysis (NASDAQ:CYTO) $0.32 -0.07 (-17.99%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$0.30▼$0.4650-Day Range$0.10▼$0.6452-Week Range$0.09▼$5.99Volume12.29 million shsAverage VolumeN/AMarket Capitalization$2.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media About Altamira Therapeutics Stock (NASDAQ:CYTO)Altamira Therapeutics Ltd., a clinical-and commercial-stage biopharmaceutical company, engages in the development of therapeutics that address various unmet medical needs in Switzerland, the United States, Europe, and Australia. The company develops OligoPhore/SemaPhore, a platform for delivery of oligonucleotides, such as small interfering ribonucleic acid or messenger RNA into target cells. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is headquartered in Hamilton, Bermuda.Read More CYTO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTO Stock News HeadlinesNovember 29, 2023 | finance.yahoo.comAltamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity RequirementNovember 20, 2023 | uk.finance.yahoo.comTrending tickers: Microsoft | Bitcoin | Altamira | AshteadDecember 3, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 17, 2023 | msn.comAltamira stock surges after deal to sell 51% stake in MedicaNovember 17, 2023 | msn.comWhy Is Altamira Therapeutics (CYTO) Stock Up 160% Today?November 17, 2023 | marketwatch.comAltamira Therapeutics Shares Surge on Sale of Bentrio UnitNovember 17, 2023 | finance.yahoo.comAltamira Therapeutics Announces Partial Spin-Off of Bentrio® BusinessNovember 10, 2023 | finance.yahoo.comAltamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal BetahistineDecember 3, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 3, 2023 | msn.comWhy Is Altamira Therapeutics (CYTO) Stock Up 28% Today?September 14, 2023 | marketwatch.comAltamira Therapeutics Shares Rise on Positive Bentrio Trial ResultsSeptember 14, 2023 | finance.yahoo.comAltamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic RhinitisSeptember 13, 2023 | insidermonkey.comAltamira Therapeutics Ltd. (NASDAQ:CYTO) Q2 2023 Earnings Call TranscriptSeptember 12, 2023 | finanznachrichten.deAltamira Therapeutics Ltd: Altamira Therapeutics Provides Business Update and First Half 2023 Financial ResultsSeptember 12, 2023 | finance.yahoo.comAltamira Therapeutics Provides Business Update and First Half 2023 Financial ResultsSeptember 8, 2023 | markets.businessinsider.comAltamira Therapeutics Ltd Registered Shs hosts conference call for investorsSeptember 6, 2023 | finance.yahoo.comAltamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12thAugust 23, 2023 | uk.finance.yahoo.comAltamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13August 23, 2023 | finance.yahoo.comAltamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13July 20, 2023 | finance.yahoo.comAltamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in ScandinaviaJuly 17, 2023 | finance.yahoo.comAltamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed JournalJuly 6, 2023 | msn.comWhy Altamira Therapeutics (CYTO) Stock Is Getting HammeredJuly 6, 2023 | finance.yahoo.comAltamira Therapeutics Announces Pricing of $5.0 Million Public OfferingJuly 5, 2023 | finance.yahoo.comAltamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac RegenerationJune 15, 2023 | finance.yahoo.comAltamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular SyndromeMay 31, 2023 | finance.yahoo.comAltamira Therapeutics Announces Publication of Peer-Reviewed Article on Peptide-Based RNA Delivery for Extrahepatic TargetsMay 24, 2023 | finance.yahoo.comAltamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic RhinitisSee More Headlines Receive CYTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Altamira Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CYTO CUSIPN/A CIK1601936 Webwww.aurismedical.com Phone(441) 295-5950Fax41-61-201-1351Employees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.32 Quick Ratio0.27 Sales & Book Value Annual Sales$320,000.00 Price / Sales6.97 Cash FlowN/A Price / Cash FlowN/A Book Value($7.38) per share Price / Book-0.04Miscellaneous Outstanding Shares6,990,000Free Float6,078,000Market Cap$2.23 million OptionableNot Optionable Beta1.69 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Thomas Meyer Ph.D. (Age 55)Founder, Chairman, CEO & MD Comp: $566.88kMr. Marcel Gremaud CPA (Age 65)Chief Financial Officer Dr. Covadonga Paneda (Age 49)Chief Operating Officer Dr. Samuel A. Wickline M.D. (Age 70)Chief Scientific Adviser Key CompetitorsAmpio PharmaceuticalsNYSE:AMPENexImmuneNASDAQ:NEXIGRI BioNASDAQ:GRIAvalo TherapeuticsNASDAQ:AVTXHistogenNASDAQ:HSTOView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 829,000 shares on 11/15/2023Ownership: 11.860%View All Institutional Transactions CYTO Stock Analysis - Frequently Asked Questions How have CYTO shares performed in 2023? Altamira Therapeutics' stock was trading at $4.85 at the beginning of the year. Since then, CYTO shares have decreased by 93.4% and is now trading at $0.3190. View the best growth stocks for 2023 here. Are investors shorting Altamira Therapeutics? Altamira Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 514,300 shares, an increase of 181.5% from the October 31st total of 182,700 shares. Based on an average trading volume of 8,950,000 shares, the short-interest ratio is currently 0.1 days. View Altamira Therapeutics' Short Interest. When did Altamira Therapeutics' stock split? Altamira Therapeutics's stock reverse split before market open on Tuesday, October 25th 2022. The 1-20 reverse split was announced on Tuesday, October 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Altamira Therapeutics' major shareholders? Altamira Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (11.86%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Altamira Therapeutics? Shares of CYTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CYTO) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altamira Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.